32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Biomacromolecules as carriers in drug delivery and tissue engineering

      review-article
      , , *
      Acta Pharmaceutica Sinica. B
      Elsevier
      ABD, albumin binding domain, ACM, aclacinomycin, ACS, absorbable collagen sponge, ADH, adipic dihydrazide, ART, artemisinin, ASF, Antheraea mylitta silk fibroin, ATRA, all-trans retinoic acid, ATS, artesunate, BCEC, brain capillary endothelial cells, BMP-2, bone morphogenetic protein-2, BSA, bovine serum albumin, BSF, Bombyx mori silk fibroin, CC-HAM, core-crosslinked polymeric micelle based hyaluronic acid, CD, cyclodextrin, CD/BP, cyclodextrin–bisphosphonate complexes, CD-g-CS, chitosan grafted with β-cyclodextrin, CD-NPs, amphiphilic MMA–tBA β-CD star copolymers that are capable of forming nanoparticles, CIA, collagen-induced arthritis, CM, collagen matrices, CMD-ChNP, carboxylmethyl dextran chitosan nanoparticle, DHA, dihydroartesunate, DOXO-EMCH, (6-maleimidocaproyl)hydrazone derivative of doxorubicin, DOX–TRF, doxorubincin–transferrin conjugate, DTX-HPLGA, HA coated PLGA nanoparticulate docetaxel, ECM, extracellular matrix, EMT, epithelial mesenchymal transition, EPR, enhanced permeability and retention, FcRn, neonatal Fc receptor, GAG, glycosaminoglycan, GC-DOX, glycol–chitosan–doxorubicin conjugate, Gd, gadolinium, GDNF, glial-derived neurotrophic factor, GO, grapheme oxide, GSH, glutathione, HA, hyaluronic acid, HA-CA, catechol-modified hyaluronic acid, HCF, heparin-conjugated fibrin, HDL, high density lipoprotein, HEK, human embryonic kidney, HSA, human serum albumin, IDL, intermediate density lipoprotein, INF, interferon, LDL, low density lipoprotein, LDLR, low density lipoprotein receptor, LDV, leucine–aspartic acid–valine, LMWH, low molecular weight heparin, MSA, mouse serum albumin, MTX–HSA, methotrexate–albumin conjugate, NIR, near-infrared, NSCLC, non-small cell lung cancer, OP-Gel-NS, oxidized pectin-gelatin-nanosliver, pDNA, plasmid DNA, PEC, polyelectrolyte, PTX, paclitaxel, RES, reticuloendothelial system, RGD, Arg–Gly–Asp peptide, rHDL, recombinant HDL, rhEGF-2/HA, recombinant human fibroblast growth factor type 2 in a hyaluronic acid carrier , SF, silk fibroin, SF-CSNP, silk fibroin modified chitosan nanoparticle, SFNP, silk fibroin nanoparticle, SPARC, secreted protein acidic and rich in cysteine, Tf, transferrin, TfR, transferrin receptor, TRAIL, tumor-necrosis factor-related apoptosis-inducing ligand, VEGF, vascular endothelial growth factor, VLDL, very low density lipoprotein, Biomacromolecule, Protein, Polysaccharide, Drug delivery, Tissue engineering

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Natural biomacromolecules have attracted increased attention as carriers in biomedicine in recent years because of their inherent biochemical and biophysical properties including renewability, nontoxicity, biocompatibility, biodegradability, long blood circulation time and targeting ability. Recent advances in our understanding of the biological functions of natural-origin biomacromolecules and the progress in the study of biological drug carriers indicate that such carriers may have advantages over synthetic material-based carriers in terms of half-life, stability, safety and ease of manufacture. In this review, we give a brief introduction to the biochemical properties of the widely used biomacromolecule-based carriers such as albumin, lipoproteins and polysaccharides. Then examples from the clinic and in recent laboratory development are summarized. Finally the current challenges and future prospects of present biological carriers are discussed.

          Graphical abstract

          This review will give an introduction of properties and applications of biomacromolecule-based carriers including proteins and polysaccharides in drug delivery systems and tissue engineering, and current challenges and prospects will be also discussed in the end.

          Related collections

          Most cited references168

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Liposomes as nanomedical devices

          Since their discovery in the 1960s, liposomes have been studied in depth, and they continue to constitute a field of intense research. Liposomes are valued for their biological and technological advantages, and are considered to be the most successful drug-carrier system known to date. Notable progress has been made, and several biomedical applications of liposomes are either in clinical trials, are about to be put on the market, or have already been approved for public use. In this review, we briefly analyze how the efficacy of liposomes depends on the nature of their components and their size, surface charge, and lipidic organization. Moreover, we discuss the influence of the physicochemical properties of liposomes on their interaction with cells, half-life, ability to enter tissues, and final fate in vivo. Finally, we describe some strategies developed to overcome limitations of the “first-generation” liposomes, and liposome-based drugs on the market and in clinical trials.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.

            Albumin is playing an increasing role as a drug carrier in the clinical setting. Principally, three drug delivery technologies can be distinguished: coupling of low-molecular weight drugs to exogenous or endogenous albumin, conjugation with bioactive proteins and encapsulation of drugs into albumin nanoparticles. The accumulation of albumin in solid tumors forms the rationale for developing albumin-based drug delivery systems for tumor targeting. Clinically, a methotrexate-albumin conjugate, an albumin-binding prodrug of doxorubicin, i.e. the (6-maleimido)caproylhydrazone derivative of doxorubicin (DOXO-EMCH), and an albumin paclitaxel nanoparticle (Abraxane) have been evaluated clinically. Abraxane has been approved for treating metastatic breast cancer. An alternative strategy is to bind a therapeutic peptide or protein covalently or physically to albumin to enhance its stability and half-life. This approach has been applied to peptides with antinociceptive, antidiabetes, antitumor or antiviral activity: Levemir, a myristic acid derivative of insulin that binds to the fatty acid binding sites of circulating albumin, has been approved for the treatment of diabetes. Furthermore, Albuferon, a fusion protein of albumin and interferon, is currently being assessed in phase III clinical trials for the treatment of hepatitis C and could become an alternative to pegylated interferon. This review gives an account of the different drug delivery systems which make use of albumin as a drug carrier with a focus on those systems that have reached an advanced stage of preclinical evaluation or that have entered clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Bio-inspired, bioengineered and biomimetic drug delivery carriers.

              Synthetic carriers such as polymer and lipid particles often struggle to meet clinical expectations. Natural particulates - that range from pathogens to mammalian cells - are therefore worth examining in more depth, as they are highly optimized for their specific functions in vivo and possess features that are often desired in drug delivery carriers. With a better understanding of these biological systems, in conjunction with the availability of advanced biotechnology tools that are useful for re-engineering the various natural systems, researchers have started to exploit natural particulates for multiple applications in the delivery of proteins, small interfering RNA and other therapeutic agents. Here, we review the natural drug delivery carriers that have provided the basis and inspiration for new drug delivery systems.
                Bookmark

                Author and article information

                Contributors
                Journal
                Acta Pharm Sin B
                Acta Pharm Sin B
                Acta Pharmaceutica Sinica. B
                Elsevier
                2211-3835
                2211-3843
                09 December 2017
                January 2018
                09 December 2017
                : 8
                : 1
                : 34-50
                Affiliations
                [0005]Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, China
                Author notes
                [* ]Corresponding author. Tel.: +86 21 51980079; fax: +86 21 5198 0079. jiangchen@ 123456shmu.edu.cn
                Article
                S2211-3835(17)30281-2
                10.1016/j.apsb.2017.11.005
                5985630
                29872621
                240a1cbf-46f8-4933-a291-ce6c90ffd069
                © 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 3 July 2017
                : 5 September 2017
                : 7 October 2017
                Categories
                Review Article

                abd, albumin binding domain,acm, aclacinomycin,acs, absorbable collagen sponge,adh, adipic dihydrazide,art, artemisinin,asf, antheraea mylitta silk fibroin,atra, all-trans retinoic acid,ats, artesunate,bcec, brain capillary endothelial cells,bmp-2, bone morphogenetic protein-2,bsa, bovine serum albumin,bsf, bombyx mori silk fibroin,cc-ham, core-crosslinked polymeric micelle based hyaluronic acid,cd, cyclodextrin,cd/bp, cyclodextrin–bisphosphonate complexes,cd-g-cs, chitosan grafted with β-cyclodextrin,cd-nps, amphiphilic mma–tba β-cd star copolymers that are capable of forming nanoparticles,cia, collagen-induced arthritis,cm, collagen matrices,cmd-chnp, carboxylmethyl dextran chitosan nanoparticle,dha, dihydroartesunate,doxo-emch, (6-maleimidocaproyl)hydrazone derivative of doxorubicin,dox–trf, doxorubincin–transferrin conjugate,dtx-hplga, ha coated plga nanoparticulate docetaxel,ecm, extracellular matrix,emt, epithelial mesenchymal transition,epr, enhanced permeability and retention,fcrn, neonatal fc receptor,gag, glycosaminoglycan,gc-dox, glycol–chitosan–doxorubicin conjugate,gd, gadolinium,gdnf, glial-derived neurotrophic factor,go, grapheme oxide,gsh, glutathione,ha, hyaluronic acid,ha-ca, catechol-modified hyaluronic acid,hcf, heparin-conjugated fibrin,hdl, high density lipoprotein,hek, human embryonic kidney,hsa, human serum albumin,idl, intermediate density lipoprotein,inf, interferon,ldl, low density lipoprotein,ldlr, low density lipoprotein receptor,ldv, leucine–aspartic acid–valine,lmwh, low molecular weight heparin,msa, mouse serum albumin,mtx–hsa, methotrexate–albumin conjugate,nir, near-infrared,nsclc, non-small cell lung cancer,op-gel-ns, oxidized pectin-gelatin-nanosliver,pdna, plasmid dna,pec, polyelectrolyte,ptx, paclitaxel,res, reticuloendothelial system,rgd, arg–gly–asp peptide,rhdl, recombinant hdl,rhegf-2/ha, recombinant human fibroblast growth factor type 2 in a hyaluronic acid carrier,sf, silk fibroin,sf-csnp, silk fibroin modified chitosan nanoparticle,sfnp, silk fibroin nanoparticle,sparc, secreted protein acidic and rich in cysteine,tf, transferrin,tfr, transferrin receptor,trail, tumor-necrosis factor-related apoptosis-inducing ligand,vegf, vascular endothelial growth factor,vldl, very low density lipoprotein,biomacromolecule,protein,polysaccharide,drug delivery,tissue engineering
                abd, albumin binding domain, acm, aclacinomycin, acs, absorbable collagen sponge, adh, adipic dihydrazide, art, artemisinin, asf, antheraea mylitta silk fibroin, atra, all-trans retinoic acid, ats, artesunate, bcec, brain capillary endothelial cells, bmp-2, bone morphogenetic protein-2, bsa, bovine serum albumin, bsf, bombyx mori silk fibroin, cc-ham, core-crosslinked polymeric micelle based hyaluronic acid, cd, cyclodextrin, cd/bp, cyclodextrin–bisphosphonate complexes, cd-g-cs, chitosan grafted with β-cyclodextrin, cd-nps, amphiphilic mma–tba β-cd star copolymers that are capable of forming nanoparticles, cia, collagen-induced arthritis, cm, collagen matrices, cmd-chnp, carboxylmethyl dextran chitosan nanoparticle, dha, dihydroartesunate, doxo-emch, (6-maleimidocaproyl)hydrazone derivative of doxorubicin, dox–trf, doxorubincin–transferrin conjugate, dtx-hplga, ha coated plga nanoparticulate docetaxel, ecm, extracellular matrix, emt, epithelial mesenchymal transition, epr, enhanced permeability and retention, fcrn, neonatal fc receptor, gag, glycosaminoglycan, gc-dox, glycol–chitosan–doxorubicin conjugate, gd, gadolinium, gdnf, glial-derived neurotrophic factor, go, grapheme oxide, gsh, glutathione, ha, hyaluronic acid, ha-ca, catechol-modified hyaluronic acid, hcf, heparin-conjugated fibrin, hdl, high density lipoprotein, hek, human embryonic kidney, hsa, human serum albumin, idl, intermediate density lipoprotein, inf, interferon, ldl, low density lipoprotein, ldlr, low density lipoprotein receptor, ldv, leucine–aspartic acid–valine, lmwh, low molecular weight heparin, msa, mouse serum albumin, mtx–hsa, methotrexate–albumin conjugate, nir, near-infrared, nsclc, non-small cell lung cancer, op-gel-ns, oxidized pectin-gelatin-nanosliver, pdna, plasmid dna, pec, polyelectrolyte, ptx, paclitaxel, res, reticuloendothelial system, rgd, arg–gly–asp peptide, rhdl, recombinant hdl, rhegf-2/ha, recombinant human fibroblast growth factor type 2 in a hyaluronic acid carrier, sf, silk fibroin, sf-csnp, silk fibroin modified chitosan nanoparticle, sfnp, silk fibroin nanoparticle, sparc, secreted protein acidic and rich in cysteine, tf, transferrin, tfr, transferrin receptor, trail, tumor-necrosis factor-related apoptosis-inducing ligand, vegf, vascular endothelial growth factor, vldl, very low density lipoprotein, biomacromolecule, protein, polysaccharide, drug delivery, tissue engineering

                Comments

                Comment on this article